Riskpilot← Back to searchSign inGet full accessNBAB, Nordic BioAnalysis AB
ABActiveOrg 5568026875Forskargatan 20 JResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20108 employees
Revenue 2024
SEK 12,8M
+27% vs 2023
EBITDA margin
4.5%
+469% vs 2023
Equity ratio
39.1%
Financial strength
Net profit 2024
SEK 372K
+217% vs 2023
| Revenue | SEK 12,8M | +27% |
| EBITDA | SEK 572K | +469% |
| Net profit | SEK 372K | +217% |
| Total assets | SEK 7,1M | +29% |
| Equity | SEK 2,8M | +15% |
| Employees | 8 | — |
Legal name
NBAB, Nordic BioAnalysis AB
Org number
5568026875
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 mars 2010
Share capital
SEK 123 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Laboratorium som utför kemiska, mikrobiologiska och immunologiska analyser primärt på läkemedel, medicintekniska substanser och produkter samt på material från prekliniskt - kliniskt utvecklingsarbete. Laboratoriet är GMP -certifierad för att utföra analyser för kvalitetskontroll.
Address
Forskargatan 20 J
Email
leo.groenewegen@norbab.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 4 316 | 4 419 | 5 586 | 7 497 | 4 259 | 8 384 | 10 030 | 12 774 |
| Staff expenses | — | — | — | — | — | — | — | — | — | −7 069 |
| EBITDA | −121 | −191 | 101 | −81 | 329 | 2 314 | 104 | −1 030 | −155 | 572 |
| Depreciation & amort. | −76 | −78 | −107 | −89 | −66 | −79 | −46 | −118 | −179 | −207 |
| EBIT | −197 | −269 | −6 | −170 | 263 | 2 235 | 58 | −1 148 | −334 | 365 |
| Net financials | −98 | −5 | −13 | −11 | −4 | 129 | — | 203 | 16 | 8 |
| Profit before tax | 36 | 7 | 140 | 2 | 259 | 2 674 | 58 | −945 | −318 | 372 |
| Tax | −32 | −3 | −32 | −1 | −57 | −575 | −13 | −0 | −0 | — |
| Net profit | 4 | 4 | 108 | 1 | 202 | 2 099 | 45 | −945 | −318 | 372 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3 240 | 2 749 | 3 342 | 2 709 | 3 219 | 5 274 | 5 447 | 5 277 | 5 537 | 7 119 |
| Equity | 1 465 | 918 | 1 325 | 1 326 | 1 528 | 3 627 | 3 673 | 2 727 | 2 409 | 2 782 |
| Long-term debt | 0 | 550 | 394 | 90 | 0 | 0 | 0 | 0 | 178 | 45 |
| Short-term debt | 843 | 629 | 1 129 | 983 | 1 380 | 1 647 | 1 775 | 2 550 | 2 950 | 4 292 |
| Total debt | 843 | 1 179 | 1 523 | 1 073 | 1 380 | 1 647 | 1 775 | 2 550 | 3 128 | 4 337 |
EBITDA margin
4.5%
This company
15.8%
Market median
-72% vs market
20162024
Equity ratio
39.1%
This company
38.2%
Market median
+2% vs market
20162024
Return on equity
13.4%
This company
18.4%
Market median
+27% vs market
20162024
Net profit margin
2.9%
This company
8.1%
Market median
-64% vs market
20162024
Asset turnover
1.79×
This company
1.12×
Market median
+60% vs market
20162024
Debt / equity
1.56×
This company
0.62×
Market median
-152% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-07-01 – 2021-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LC Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
LG Audit | Audit | 2022 | — | — |
CJ Chief Auditor | Chief Auditor | 2025 | — | — |
BL | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ilya Pharma AB (publ) | Company | 79.0% | 79.0% | 2026 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Ilya Pharma AB (publ)
NBAB, Nordic BioAnalysis AB Board members of NBAB, Nordic BioAnalysis AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leo Cornelis Groenewegen | Chief Executive Officer | 0 companies |
| Lars Gustaf Kylberg | Audit | 0 companies |
| Claes Jihmmy Ingvarsson | Chief Auditor | 0 companies |
| Bo Lennart Harritz Lindh | Audit | 0 companies |
| Peter Mats Tore Frank | Board of Directors | 0 companies |
| Evelina Wanda Matilda Vågesjö | Board of Directors | 0 companies |
| Nils Henrik Didner | Board of Directors | 0 companies |
| Patricia Grigoleit | Chairman | 0 companies |
| Jack Jiang Yu | Board of Directors | 0 companies |
| Kerstin Margareta F Andersson | Board of Directors | 0 companies |
| Christer Nils-Erik Johansson | Chairman | 0 companies |
| Mona Christina Johansson | Deputy Board Member | 0 companies |
| Daniel Mathias Haid | Board of Directors | 0 companies |
| Oskar Henrik Gauther Lund | Chairman | 0 companies |
| Lovisa Margareta Ringstad | Board of Directors | 0 companies |
| Göran Beijer | Board of Directors | 0 companies |